Amneal Pharmaceuticals AMRX
United StatesHealthcare · Drug Manufacturers - Specialty & GenericUSD
22.71 USD (+15.6%)
7 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Amneal Pharmaceuticals is a U.S. pharmaceutical company that develops, manufactures, and markets generic and branded medications, with a diversified business model across specialties and generics.
Key points
from its scores- ✓Good share-price trend9.5
- ✓Strong growth8.4
- ✕Little or no dividend1.5
- ✕Demanding valuation3.4
- ✕Unfavourable risk and backdrop4.7
AI analysis
bottom line, main risk, context and newsStrong growth and an attractive forward valuation are offset by high leverage and negative cash generation, which require monitoring.
Amneal shows exceptional earnings growth of 157% and an ROIC of 20.2%, but its high debt (ND/EBITDA 3.86) and negative cash conversion (-16.7%) weigh on its financial health and valuation, with a forward P/E of 16.48 suggesting potential if it deleverages.
The main risk is high leverage (Net Debt/EBITDA of 3.86) combined with negative free cash flow conversion, which could limit its ability to invest and refinance in a rising rate environment.
Context and risks
Amneal operates in the U.S. pharmaceutical sector, subject to regulatory and pricing pressure, and its high leverage (Net Debt/EBITDA of 3.86) exposes it to a rising interest rate environment, increasing refinancing costs. Governance in the U.S. is solid, but regulatory and balance sheet risks are material for this company.
Is Amneal Pharmaceuticals stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 20% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 40.1 | 26.7 | +50% |
| EV / EBITDA | 13.1 | 14.5 | −10% |
| Price / book | 190.8 | 4.1 | +4,544% |
| Price / sales | 2.2 | 3.4 | −36% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.4 out of 10 (median for Healthcare: 4.7).
Average analyst target: 22.71 USD, +15.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 6.2 (sector 5.5), Growth 8.4 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 40.1
- Forward P/E
- 16.5
- EV / EBITDA
- 13.1
- Price / book
- 190.8
- Price / sales
- 2.2
- PEG
- 1.93
- Market cap
- 6.8B USD
- Enterprise value
- 9.0B USD
Profitability
- ROE
- 613.0%
- ROA
- 8.6%
- ROIC (approx.)
- 20.2%
- Gross margin
- 39.8%
- Operating margin
- 18.3%
- Net margin
- 5.0%
- Free cash flow
- −115.3M USD
- FCF yield
- −1.7%
- Cash conversion
- −17%
Solvency
- Total debt
- 2.8B USD
- Net debt
- 2.7B USD
- Cash
- 131.4M USD
- EBITDA
- 689.4M USD
- Net debt / EBITDA
- 3.86
- Debt / equity
- 2,386.53
- Current ratio
- 2.21
- Quick ratio
- 1.38
Growth
- Revenue growth
- +9.9%
- Earnings growth
- +157.1%
- EPS (TTM)
- 0.49 USD
- EPS (forward)
- 1.19 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.22
- Analyst consensus
- Strong buy (7)
- Target price
- 22.71 USD
- 52-week range
- 9.56 – 21.18
Recent news
All AMRX news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Amneal Pharmaceuticals
Is Amneal Pharmaceuticals stock cheap or expensive?
On P/E and EV / EBITDA, it trades 20% above the Healthcare median on average. Valuation score: 3.4 out of 10 (median for Healthcare: 4.7). Average analyst target: 22.71 USD, +15.6% versus the price. This is not investment advice.
What score does Amneal Pharmaceuticals get on MeridIAn Screener?
It scores 5.4 out of 10, rank 1,452 of 2,130 (better than 29% of the companies analysed). Its strongest category is Momentum (9.5) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is Amneal Pharmaceuticals's P/E ratio?
Its P/E is 40.1: the share price equals 40.1 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 16.5.
How much is Amneal Pharmaceuticals worth on the stock market?
Its market capitalisation is 6.8B USD and its enterprise value, debt included, is 9.0B USD.
How much debt does Amneal Pharmaceuticals have?
Its net debt (debt minus cash) is 2.7B USD. That is 3.86 times its EBITDA; the Healthcare median is 1.53.
Does Amneal Pharmaceuticals pay a dividend?
It pays no dividend, or almost none.
How has Amneal Pharmaceuticals stock performed over the last year?
It has risen 97.1% over the last year, excluding dividends. Over the last 52 weeks it has traded between 9.56 and 21.18 USD. Past performance does not guarantee future results.
What do analysts think of Amneal Pharmaceuticals?
7 analysts cover it; their average recommendation is “Strong buy” and their average target is 22.71 USD (+15.6% versus the price). It is an estimate, not market data.